Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation: The ICSLIFE pragmatic, randomised controlled study
Alberto Papi,Giacomo Forini,Mauro Maniscalco,Elena Bargagli,Claudia Crimi,Pierachille Santus,Antonio Molino,Valeria Bandiera,Federico Baraldi,Silvestro Ennio D'Anna,Mauro Carone,Maurizio Marvisi,Corrado Pelaia,Giulia Scioscia,Vincenzo Patella,Maria Aliani,Leonardo M Fabbri,ICSLIFE Study Group,Giuseppina Schipani,Raffaele Antonello Incalzi,Paola Rogliani,Piero Ceriana,Antonio Spanevello,Bruno Balbi,Maria Pia Foschino,Nicola Scichilone,Ombretta Para,Carlo Nozzoli,Francesco Dentali,Bianca Beghè,Manlio Milanese,Eugenia Monaco,Angelo Guido Corsico,Nicola Facciolongo,Carlo Barbetta,Martina Bonifazi,Micaela Romagnoli,Fabiano di Marco,Andrea Bianco,Enea Tazzari,Luca Ronzoni,Federica Santoli
DOI: https://doi.org/10.1016/j.ejim.2024.07.001
2024-07-08
Abstract:Introduction: Patients with chronic obstructive pulmonary disease (COPD) frequently have cardiovascular comorbidities, increasing the risk of hospitalised COPD exacerbations (H-ECOPDs) or death. This pragmatic study examined the effects of adding an inhaled corticosteroid (ICS) to long-acting bronchodilator(s) (LABDs) in patients with COPD and cardiac comorbidities who had a recent H-ECOPD. Methods: Patients >60 years of age with COPD and ≥1 cardiac comorbidity, within 6 months after discharge following an H-ECOPD, were randomised to receive LABD(s) with or without ICS, and were followed for 1 year. The primary outcome was the time to first rehospitalisation and/or all-cause death. Results: The planned number of patients was not recruited (803/1032), limiting the strength of the conclusions. In the intention-to-treat population, 89/403 patients (22.1 %) were rehospitalised or died in the LABD group (probability 0.257 [95 % confidence interval 0.206, 0.318]), vs 85/400 (21.3 %) in the LABD+ICS group (0.249 [0.198, 0.310]), with no difference between groups in time-to-event (hazard ratio 1.116 [0.827, 1.504]; p = 0.473). All-cause and cardiovascular mortality were lower in patients receiving LABD(s)+ICS, with relative reductions of 19.7 % and 27.4 %, respectively (9.8 % vs 12.2 % and 4.5 % vs 6.2 %), although the groups were not formally statistically compared for these endpoints. Fewer patients had adverse events in the LABD+ICS group (43.0 % vs 50.4 %; p = 0.013), with 4.9 % vs 5.4 % reporting pneumonia adverse events. Conclusions: Results suggest addition of ICS to LABDs did not reduce the time-to-combined rehospitalisation/death, although it decreased all-cause and cardiovascular mortality. ICS use was not associated with an increased risk of adverse events, particularly pneumonia.